Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19

NCT04360096 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

144

Enrollment

OTHER

Sponsor class

Stopped Sponsor decision

Conditions

SARS-CoV 2
COVID
ARDS
ALI
Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Dyspnea

Interventions

DRUG: ZYESAMI™ (aviptadil acetate)
DRUG: Placebo
DEVICE: Nebulized administration of ZYESAMI™ or Placebo

Sponsor

APR Applied Pharma Research s.a.